Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Alzheimer’s Disease Diagnostics and Therapeutics Market is segmented by Product (Therapeutics (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Other Therapeutics) and Diagnostics (Brain Imaging and CSF Test for Alzheimer’s Disease)) and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the market size and forecasts in value (USD million) for the above segments.

Market Snapshot

Alzheimer’s Disease Diagnostics and Therapeutics Market Bar Graph
Study Period: 2018-2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.36 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Alzheimer’s disease diagnostics and therapeutics market was valued at USD 6,632.82 million in 2020, and it is expected to reach approximately USD 9,073 million in 2026, registering a CAGR of nearly 5.36% during the forecast period, 2021-2026. The study titled, "Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a UK Biobank study", published in November 2020, exhibited that patients suffering from dementia are at the highest risk of mortality from COVID-19. Hence, this is expected to create new opportunities for novel treatments and diagnosis in the market studied.

The key factors propelling the growth of this market are the increasing prevalence of chronic diseases like dementia, increasing pipeline drug development, investment in biomarkers for drug development, and increasing sophisticated diagnostics for early detection. According to the World Alzheimer Report, in 2019, around 50 million people worldwide were reported to be suffering from Alzheimer's and related dementia, and this number is further expected to reach 152 million by 2050.​

The extensive research studies being conducted related to Alzheimer's disease are further accelerating the market growth. For instance, in October 2020, ImmunoBrain Checkpoint Inc. was funded USD 1,000,000 by the Alzheimer’s Association to aid the Phase 1 clinical trial for "IBC-Ab002" in the treatment of Alzheimer's. This is expected to accelerate the market growth. Also, the National Institute of Health reported that in July 2019, there were 132 agents in clinical trials for AD; 28 agents were in 42 Phase 3 trials, 74 agents were in 83 Phase 2 trials, and 30 agents were in 31 Phase 1 trials. There was an increasing number of agents in each phase compared to the 2018 pipeline. Hence, the increasing number of clinical studies for diagnosis and treatment of Alzheimer's is expected to drive the market growth.

However, high failure rates of clinical studies related to diagnosis and treatment of Alzheimer's are expected to hinder the market growth.

Scope of the Report

As per the scope of the report, Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons that results in loss of memory, thinking and language skills, and behavioral changes. There is a rapid growth in the number of people living with Alzheimer’s disease, and only around one in four people with the disease gets diagnosed. The Alzheimer’s disease diagnostics and therapeutics market is segmented by product (therapeutics (cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutics) and diagnostics (brain imaging and CSF test for Alzheimer’s disease)) and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the market size and forecasts in value (USD million) for the above segments.

By Product
Cholinesterase Inhibitors
NMDA Receptor Antagonists
Other Therapeutics
Brain Imaging
CFS Test for Alzheimer's Disease
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Cholinesterase Inhibitors are Expected to Hold the Highest Market Share in the Therapeutics Segment

Cholinesterase inhibitors are believed to have the largest market size, and they are expected to witness a high CAGR during the forecast period. During this pandemic situation, cholinesterase is being studied extensively for its safety, efficacy, and side effects in Alzheimer's patients with COVID-19 infection. As per the study titled, "Potential Novel Role of COVID-19 in Alzheimer’s Disease and Preventative Mitigation Strategies", published in June 2020, the cholinergic anti-inflammatory pathway was observed to be a viable target to control inflammation and for the prevention of cytokine storm post detection of COVID-19 virus infection in Alzheimer's patients, and acetylcholinesterase inhibitors can potentially be administered as an adjunctive therapy.

Cholinesterase inhibitors can slightly delay the loss of brain function in people who have mild to moderate Alzheimer’s disease. Cholinesterase inhibitors are prescribed to treat symptoms related to memory, thinking, language, judgment, and other thought processes. Some of the drugs approved by the United States Food & Drug Administration are Aricept, Exelon, and Razadyne indicated against mild to moderate Alzheimer's.

Furthermore, companies are investing in the development of new drugs. For instance, in January 2020, Corium International Inc. filed a New Drug Application (NDA) for ADLARITY (donepezil transdermal system) indicated for the treatment of Alzheimer’s disease. Hence, owing to the developments, the cholinesterase inhibitors segment is expected to grow during the forecast period.

Alzheimer’s Disease Diagnostics and Therapeutics Market key Trends

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America currently dominates the market for Alzheimer’s disease diagnostics and therapeutics, and it is expected to continue its stronghold for a few more years. The United States holds the largest share of the market. However, there have been many reports of neurologic complications associated with COVID-19. The COVID-19 pandemic has also caused drastic changes in Alzheimer's patients’ normal routine with social distancing and lockdowns in place in the United States. Understandably, many Alzheimer's patients have experienced a negative impact on their mental health.

The rising geriatric population is one of the key factors responsible for the market growth in this country, as the older population is at a higher risk of acquiring the disease. As per the United States Census Bureau data, in 2019, about 54 million Americans were aged 65 years and above. Furthermore, according to the Alzheimer’s Association, more than 5.8 million Americans suffer from Alzheimer’s disease, as of 2020. Hence, the rising geriatric population, coupled with the rising burden of the disease, is expected to boost the demand for diagnostics and treatment in this country.

The United States is considered to be the global leader in Alzheimer’s disease intervention and management. According to the Alzheimer's Association, the total healthcare expenditure on patients with dementia was estimated to be USD 357,297 in 2019. Overall, the market is expected to register a healthy CAGR over the forecast period.

Furthermore, the increasing number of research studies related to the diagnosis and management of Alzheimer's disease is expected to drive the market growth. According to the National Clinical Trials Registry (NCT), in the United States, currently, there are about 144 active clinical trials under development for Alzheimer’s disease across different phases. Due to the COVID-19 outbreak in the country, the number of clinical trials is expected to increase at a slow pace due to the lack of resources and patients’ availability.

Alzheimer’s Disease Diagnostics and Therapeutics Market Share By Region

Competitive Landscape

The Alzheimer’s disease diagnostics and therapeutics market is moderately competitive and consists of several major players. With technological advancements and product innovation, mid-size to smaller companies are expanding their market presence by introducing new technologies with better results. Companies like F. Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., and Eli Lily and Co. hold substantial shares in the market.

Recent Developments

  • In December 2020, C2N Diagnostics launched its ''Percivity AD Blood Test'' in the European region after the approval from the European Union. It is an in vitro diagnostic method based on mass spectrometry used for the diagnosis of Alzheimer’s disease pathology.
  • In August 2020, Biogen and Eisai Co. Ltd announced the approval of the Biologics License Application by the United States Food & Drug Administration (US FDA) for ''aducanumab'', which is being studied for the treatment of Alzheimer's disease. In January 2021, the FDA extended the review period to three months for the same.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Use of Biomarkers in Diagnosis and Drug Development

      2. 4.2.2 Large Number of Drugs in Pipeline

      3. 4.2.3 Emerging Novel Diagnostic Technologies

    3. 4.3 Market Restraints

      1. 4.3.1 High Failure Rates of Late-stage Drugs

      2. 4.3.2 Lack of Surrogate Markers and Challenges in Early Diagnosis

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value)

    1. 5.1 By Product

      1. 5.1.1 Therapeutics

        1. Cholinesterase Inhibitors

        2. NMDA Receptor Antagonists

        3. Other Therapeutics

      2. 5.1.2 Diagnostics

        1. Brain Imaging

        2. CFS Test for Alzheimer's Disease

    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.2.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 F. Hoffmann-La Roche

      2. 6.1.2 Novartis AG

      3. 6.1.3 Merck & Co. Inc.

      4. 6.1.4 Pfizer Inc.

      5. 6.1.5 Eisai Co. Ltd

      6. 6.1.6 Biogen Inc.

      7. 6.1.7 Johnson & Johnson

      8. 6.1.8 Eli Lilly and Company

      9. 6.1.9 Lupin Limited

      10. 6.1.10 Abbvie Inc (Allergan)

      11. 6.1.11 Siemens Healthineers

      12. 6.1.12 Zydus Cadila

      13. 6.1.13 Merz Pharma

      14. 6.1.14 Teva Pharmaceutical Industries Ltd

      15. 6.1.15 Adamas Pharmaceuticals Inc.

    2. *List Not Exhaustive

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Alzheimer's Disease Diagnostics and Therapeutics Market market is studied from 2018 - 2026.

The Global Alzheimer's Disease Diagnostics and Therapeutics Market is growing at a CAGR of 5.36% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., Eli Lilly and Company, Merck & Co. Inc. are the major companies operating in Global Alzheimer's Disease Diagnostics and Therapeutics Market .

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!